shutterstock_1960556293_molly_woodward

Molly Woodward / Shutterstock.com

15 February 2024Big PharmaLiz Hockley

Pfizer to pay out $93m to end antitrust suit

US pharma firm has not admitted liability as part of agreement with Lipitor buyers following a long-running dispute over a cholesterol drug | Litigation against Sun Pharma’s Ranbaxy will continue.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pfizer and BioNTech allege inconsistencies in Moderna’s COVID-19 statements

1 February 2024 Pharma giants raise concerns about Moderna’s COVID-19 vaccine patents | Company's statements to the FDA and PTAB contain "inconsistencies" | Appeals Board urged to scrutinise assertions.

Moderna and Pfizer face fresh suits over COVID-19 vaccine

30 May 2023 A US biotech is accusing the pair of infringing several of its “foundational” lipid particle patents | Pfizer and BioNTech accused plaintiff in earlier suit of antitrust in a dispute over one of the patents at issue.

More on this story

Moderna and Pfizer face fresh suits over COVID-19 vaccine

30 May 2023 A US biotech is accusing the pair of infringing several of its “foundational” lipid particle patents | Pfizer and BioNTech accused plaintiff in earlier suit of antitrust in a dispute over one of the patents at issue.

Pfizer and BioNTech allege inconsistencies in Moderna’s COVID-19 statements

1 February 2024 Pharma giants raise concerns about Moderna’s COVID-19 vaccine patents | Company's statements to the FDA and PTAB contain "inconsistencies" | Appeals Board urged to scrutinise assertions.

More on this story

Moderna and Pfizer face fresh suits over COVID-19 vaccine

30 May 2023 A US biotech is accusing the pair of infringing several of its “foundational” lipid particle patents | Pfizer and BioNTech accused plaintiff in earlier suit of antitrust in a dispute over one of the patents at issue.

Pfizer and BioNTech allege inconsistencies in Moderna’s COVID-19 statements

1 February 2024 Pharma giants raise concerns about Moderna’s COVID-19 vaccine patents | Company's statements to the FDA and PTAB contain "inconsistencies" | Appeals Board urged to scrutinise assertions.

More features

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

UPC deals further blow to Dexcom in glucose monitor dispute with Abbott

‘A marathon and a sprint at the same time’: How we won $452m damages